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A growing number of clinical trials incorporate invasive procedures like nondiagnostic tumor biopsies for biomarker or pharmacodynamic 
analysis.1 Such invasive research procedures are ethi-
cally contentious. Tumor biopsies involve pain and 
complication risk,2 and at least one procedure-related 
death has been reported.3 However, nondiagnostic tu-
mor biopsies obtained in the research context generally 
have no value for managing the participant’s medical 
condition. Some commentators therefore argue that 
research biopsies “take” from participants without 
“giving in return.”4
Because such procedures are conducted contrary 
to research participants’ medical interests, an ethical 
framework for enrolling patients in studies that include 
a research biopsy rides heavily on informed consent. In 
particular, study participants should understand that 
research biopsies are nontherapeutic and burdensome 
and that participation is discretionary in studies involv-
ing them. Yet little is known about whether decisions 
to enroll in a study that involves a research biopsy, 
including those that permit participants to opt out of 
the procedure, meet thresholds of consent validity, in 
other words, whether individuals sufficiently under-
stand and appreciate the consequences of their decision 
and whether they are not unduly influenced.5 Some 
studies about research biopsies suggest that individuals 
often misconstrue nondiagnostic biopsies as therapeu-
tic;6 others suggest the contrary.7 Interpreting these 
findings is further complicated by the fact that because 
participants were often enrolled in clinical drug trials, 
they might have legitimately imputed therapeutic value 
to research biopsies when receiving access to investiga-
tional drugs was conditioned on providing a biopsy for 
research.8
There are at least three reasons that clinical trials 
that include research biopsies might present challenges 
for consent validity. First, because procedures are bur-
densome, individuals who enroll in these trials might 
do so under the mistaken belief that the biopsies pro-
vide a therapeutic benefit to them. Second, biopsies are 
often conducted proximate to therapeutic encounters, 
where patients undergoing a biopsy might be focused 
on a recent diagnosis and on management options, 
not on their role as a research participant. Last, some 
argue that because research participants often conflate 
research with clinical care,9 they might fail to appreci-
ate the nontherapeutic nature of a research biopsy. To 
investigate these issues, we used semistructured inter-
views to probe recalled perceptions, motivations, and 
consent quality for research participants in a cancer 
biomarker study involving nondiagnostic biopsies.
Study Methods
Our primary goal was to describe the extent to which research participants with confirmed breast 
cancer diagnoses ascribed therapeutic orientation to 
nondiagnostic tumor biopsies in biomarker studies 
(hereinafter “parent studies”) in which they had previ-
ously participated. Our study was conducted at a major 
cancer research and treatment hospital in metropolitan 
Montreal.
Prospective participants for the biomarker studies 
arrived at the research site—a breast cancer clinic—on 
referral after a positive mammogram. In the first ap-
pointment, these patients were informed of the need 
for a diagnostic biopsy and approached about enroll-
ing in three studies involving nondiagnostic breast 
tumor biopsies. Consent for research biopsies was 
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sought during the patients’ initial visits by the head 
nurse (responsible for intake of patients at the clinic, 
discussing diagnostic biopsies, and overseeing research), 
and research biopsies were obtained by a radiologist 
(not the principal investigator or care surgeon) in the 
same session during which clinically indicated biopsies 
were collected (except in one case, where a participant 
received diagnostic and research biopsies on a return 
visit). Research biopsies required additional needle 
trajectories; three were sought from each patient, and a 
research nurse was present during the procedures. Biop-
sies were performed either during the first meeting or a 
few days later. All women received standard of care for 
their cancer, and none were participating in drug trials. 
The benefits section of the consent documents stated, 
“There will be no direct benefit to you by taking part 
in this research . . . . While not directly offering you a 
specific therapeutic benefit, the careful follow-up may 
well represent a degree of improved quality of care for 
you.” As a condition of granting us access to partici-
pants in the parent studies, the biomarker research 
team required that we interview women after the last 
follow-up session for the parent studies.
n Semistructured Interviews. The theory guiding 
our interview template is described elsewhere.10 Briefly, 
we designed a 30-minute interview template probing 
three domains: motivation for enrollment, compre-
hension, and voluntariness. Participants in the parent 
studies were approached to participate in our interview 
study after their last research follow-up—typically six 
months after undergoing the research biopsies. We 
also conducted 20-minute interviews with the princi-
pal investigator (a surgeon-oncologist) of the parent 
studies and the head nurse to assess their perception of 
informed consent quality; interviews were recorded and 
transcribed. 
Interviews were conducted in English by Roberto 
Abadie, between December 2011 and April 2012, 
recorded, and transcribed. Coding was performed 
independently by Roberto Abadie and Jonathan Kim-
melman, using an iterative process. Interviews were 
interpreted using grounded theory.11 This facilitated 
development of analytically meaningful coding schemes 
and attachment of codes to text segments. We mea-
sured the frequency with which codes appeared. Cod-
ings were compared until a consensus was reached on 
categories and definitions. Following Miles and Hu-
berman,12 we targeted inter-rater agreement of 80%. 
Analysis ended once all transcripts had been coded and 
saturation obtained (a list of codes is available from the 
Table 1.  
Demographics of Patient-Respondents
Individual Age (yrs)  Race/Ethnicity  Highest Educational Level  Date of First Diagnosis
N01   34  White   Bachelor’s degree   January 2011
 
N02  84  White/Italian  Fifth grade   1990  
N03  60  White   Bachelor’s degree   September 2010
N04  47  White/Middle Eastern Bachelor’s degree   March 2011
     
N05  43  White   High school graduate  2010    
   
N06  62  Asian/Pakistani  High school graduate  January 2011
     
N07  47  White/Mohawk  High school graduate  December 2010
     
N08  42  White/Middle Eastern Master’s degree   November 2011
N09  67  White/Portuguese Fifth grade   1998
N10  48  White/Ashkenazi   Bachelor’s degree   2009 
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authors). The study was approved by the institutional 
review board (IRB) at the hospital hosting the parent 
study, and all participants provided written informed 
consent.
Study Results
All of the individuals approached (10 in total) agreed to participate in our interview study. 
We were unable to interview patients declining re-
search biopsies, primarily because refusal was rare. 
Table 1 shows the demographics of participants we 
interviewed. Most of the participants were Cauca-
sian, though the sample was diverse in terms of age, 
socioeconomic status, and length of time since initial 
diagnosis. Two patients entered the parent study after 
relapse (patients N02 and N09). The mean time be-
tween biopsy and interview was 14.18 months (range: 
2-30 months).
n Motivation for Enrolling in Biopsy Study. We 
began the interview by asking why each woman had 
agreed to undergo research biopsies. Without excep-
tion, respondents offered reasons rooted in altruism, 
for instance: “If we can help another patient in the fu-
ture, by all means, let’s help” (N02). And as described 
below, some responses were tinged with expressions of 
reciprocity toward previous study subjects or the study 
team.
Respondents often appealed to their identification 
with other members of society in explaining their moti-
vations. One respondent said, for example, 
I am like you, and you are like me, and I am like my 
family, like my neighbor, your mother, your sister. We 
are all people on this planet, and I feel like they all are 
like me. And if they can benefit from what I do in the 
future, then it is good. My daughter, maybe 20, 30 
years from now might be diagnosed. (N07) 
Consistent with previous studies of nontherapeutic 
research,13 responses often evoked benefits flowing to 
family members. In no instance did respondents de-
scribe primary motivators as therapeutic or diagnostic 
access or collateral benefits like extra contact with the 
study team.
n Comprehension of Benefits and Purpose. When 
asked about direct benefits of participation, all respon-
dents accurately stated that there were none: “[I]mme-
diate expectations from this would be nil,” one stated. 
I never expected that” (N02). We probed with slightly 
different wording for confirmation. In every case, 
respondents accurately stated that there were no direct 
benefits from the research biopsies. The investigators of 
the parent study correctly predicted this nontherapeu-
tic orientation. Nevertheless, we occasionally heard a 
response that attributed indirect benefits to participa-
tion, including the prospect that discoveries might be 
relevant to participants, as well as increased monitor-
ing. For instance, once respondent noted that “anytime 
that I had a question, if I felt funny, or if it was some-
thing new because I am very vigilant of anything that 
happens to me, I call my nurse, I call Dr. X’s secretary, 
and if needed, I can be at the hospital if not the same 
day, the day after” (N01).
Most respondents were also able to accurately state 
that they had participated in a research study. However, 
two harbored misunderstandings. In one case, a respon-
dent (the one who described “helping other women” 
as her primary motivation for enrollment) believed that 
the biomarker study involved a “phase IV” drug trial 
(N10). Another respondent seemed unable to recall she 
had undergone a research biopsy: “I don’t think we re-
ally were asked to do anything extra. I don’t think they 
told us, we are doing this because of the research only.” 
(N02)
Despite emphatically altruistic motivations for en-
rolling in the parent studies, respondents were disen-
gaged from the substance of the research. The consent 
form stated,
The purpose of this study is to understand why tumors 
become resistant to anticancer treatment. To under-
stand clinical resistance, we need to obtain small pieces 
of tumor (biopsies) from your primary breast lesions . 
. . we hope to understand resistance to the particular 
anticancer treatment that you are receiving . . . we want 
to find markers that are associated with resistance to 
the anticancer treatment. Markers are proteins found in 
tumor tissue . . . that are resistant to treatment.
However, none of the respondents could state the 
study’s purpose. One respondent’s answer was, “I don’t 
know. I was under the impression that they were taking 
samples and then researchers would do research using 
my tissue” (N07). And another respondent said, “Why 
Because nondiagnostic research biopsies are 
conducted contrary to research participants’  
medical interests, an ethical framework for  
enrolling patients in studies that include a research 
biopsy rides heavily on informed consent.
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is he doing this? I guess it is because he has a research 
clinic and he wants further improvement for breast 
cancer in women” (N03). The medical team accurately 
surmised that participants in their study would be dis-
engaged with the research objectives. As one principal 
investigator predicted, “They wouldn’t know that we 
are sequencing the tumor . . . but they might know that 
we are doing research to understand how the tumors 
work.”
Few of the respondents reported contemplating fu-
ture impacts of research findings, though according to 
one respondent, “You hope [advances] are possible, but 
I don’t think about that” (N05). Most were unable to 
estimate the probability that the studies would produce 
a major medical advance. One respondent said, “I’ll say 
50/50; I don’t have a clue, no clue” (N04), and another 
said, “I have no knowledge of research” (N06). When 
pressed, many respondents offered expectations exceed-
ing historic odds of medical breakthroughs. When 
asked whether long odds of a breakthrough might have 
deterred their enrollment, one respondent’s resolve to 
participate seemed to intensify: “We need even more 
because if you have a smaller rate of success, you need 
more people and everything to make progress” (N05).
n Recall and Perception of Risk. Breast tumor 
biopsies are associated with discomfort and complica-
tion risk. We probed the extent to which respondents 
understood risk and drew on this knowledge in their 
decision-making about enrolling in the biopsy study. 
Even after having participated in the parent study, 
many participants were unable to recall any risks, and 
some reported being indifferent to burdens at the time 
of deciding whether to enroll. According to one respon-
dent, “[The biopsy] didn’t seem like a big deal because 
it didn’t take very long and it is not that invasive” 
(N01). The following dialogue captures the spirit of 
many responses:
Interviewer: [W]hen you do the biopsy for diagnosis, 
you have two tissue samples, and then if you do the 
research biopsy, you undergo three more additional 
extractions.
N06: [Smiles.] [O]ne time, two times, three times, four 
times. It doesn’t matter! 
Interviewer: You were not worried about the pain or 
the bleeding?
N06: No. I wanted to help other people, and also some 
pain and bleeding are to be expected.
When asked to recall the biopsy, most respondents 
described burdens as modest to minor. Said one respon-
dent, “I had a little bit of bruising after the biopsy, but 
it was not a concern. It didn’t scare me, and it didn’t 
concern me” (N05). Yet when asked to rate the pain 
on a scale from 1 to 10 (with 10 being the highest), re-
spondents generally scored pain at 5 or 6. Some noted 
that, in contrast with those associated with chemother-
apy, biopsy burdens were transient and did not threaten 
physical identity, by, for instance, rendering a patient 
publicly ill the way hair loss can. However, two re-
spondents considered burdens significant and described 
them as equal to or greater than chemotherapy. One 
respondent applied a score of 9 to the biopsy, describ-
ing it as “very painful” (N06). Another respondent em-
phasized experiential aspects of the procedure: “[I]t is 
very invasive. The needle is big, but that doesn’t bother 
me. What bothers me, it’s the click; it is like a point 
that comes and grabs the tissue . . . . I remember myself 
thinking, I wish it’s a good one, I don’t want them to 
take more, make it a good one” (N07). No respondents 
reported being surprised about the level of burden.
n Voluntariness. Along with capacity and compre-
hension, freedom from undue influence is an essential 
element of valid consent.14 We asked a series of ques-
tions about perceptible factors that might have adverse-
ly affected voluntary decision-making.
Respondents did not report any pressure to enroll 
in the parent study and reportedly perceived ample 
opportunity to query investigators and to decline to 
participate. When asked whether declining might have 
adversely affected their medical care, respondents 
generally replied in the negative: “I don’t think that Dr. 
X would treat me any different if I agree to participate 
or not to participate” (N08). Yet, two participants sug-
gested that this was a possibility: “That’s a good ques-
tion,” one replied (N01), and another said, “I think 
being part of the study, the treatment . . . I was better 
treated, I think . . . better supported . . . better fol-
lowed . . . . Maybe they were more ‘there’ because they 
needed certain things or they needed to know more or 
how I felt or what I did” (N04).
n Decision-Making Process. To better understand 
why many respondents seemed unperturbed by re-
search burdens, we asked a series of questions about 
the decision-making process. Many respondents said 
enrolling in the parent study was an easy decision to 
make. One replied, for example, “To be honest, didn’t 
give it a lot of thought” (N02). Another said, “I wanted 
to sign it the same day, but the oncology nurse was 
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not there anymore so I think that it was a week after” 
(N10). Three respondents recalled asking questions 
about the research, and enrolling in the parent study 
gave one respondent pause. “[I]initially,” she explained, 
“we didn’t know how much tissue he was going to 
remove and . . . we were a little bit concerned that 
because of this study he was going to remove some 
nodes no matter what, but then he told us that he was 
going to remove them anyway. So I didn’t see any harm 
in participating” (N01). Most respondents recalled that 
the research decision-making context was distracting 
and overwhelming. In some cases, this led to indiffer-
ence. As one respondent said, 
We have so many things in our minds, [research] is 
the least of our concerns [laughs] . . . . [I] think that 
[subjects] are probably not well informed but not 
because the information isn’t there. It is just that the 
concerns they are dealing with, whether they are going 
to go through or not, that’s their main concern. I mean, 
clearly, that’s the priority for them. (N02) 
Yet some respondents said they were overwhelmed, 
with one explaining, 
[I]t is so much information, getting all the documents, 
absorbing all the information is hard. . . . I couldn’t 
process all the information; even after, I would ask, 
What did he say? We are relatively educated people and 
can ask questions, so I can imagine how other people 
that might be older or with fewer resources, or another 
language might have more difficulty understanding. 
(N01) 
Another respondent described the consent process as 
follows: “They tell you okay, we are going to do this 
and this and this. You are not mentally there; you are 
in shock” (N05).
n Additional Themes. Our interviews uncovered 
several additional themes. First, though some respon-
dents expressed skepticism about medicine or research, 
all showed unswerving confidence in both the institu-
tion and study team. As one stated, “I don’t expect 
the research performed at [institution] to be harm-
ful” (N01). Respondents also deferred all aspects of 
moral decision-making or science to the institution or 
researchers. For instance, some said they were comfort-
able knowing little if anything about the research. “I 
don’t need to know everything,” one respondent said. 
“I don’t want him to waste time, so I said, Where do I 
sign? As I said before, I really trust them” (N05). And 
another said, “I am sure that there are people [at the 
hospital] that struggle with [the risk or benefit]” (N01).
Even in this unusual research setting where research 
procedures occurred outside of a trial where drugs 
were being administered, another theme emerged from 
accounts of research intertwined with those of care. In 
particular, beliefs and convictions arising out of care 
shaped the research encounter. The following quota-
tion, prompted by a question about concerns on enter-
ing the parent study, illustrates the way trust, built in 
the care setting, grounded confidence in the research: “I 
put my trust in [the physician-investigator] and in God. 
First God [laughs]. The first time I met [the physician-
investigator]—he is such a sweet person. I was scared; 
I was discouraged; I asked [him], ‘Do you believe in 
God?’ He said, ‘Yes.’ I said, ‘Me too, let’s work at this 
together!’” (N03)
Finally, the theme of reciprocity also emerged. Some 
respondents regarded participation as an act of care 
for the investigators: “It’s me almost saying, ‘What 
can I do to help you?’” one said (N05), and another 
explained, “Sometimes I would ask Dr. X, ‘So, was I a 
good patient for you, a good subject?’” (N02)
Discussion
The interview responses from our study paint a reas-suring picture about informed consent for research 
biopsies, at least for the parent studies from which our 
respondents were recruited. Respondents did not dem-
onstrate a propensity to view an invasive nondiagnostic 
biopsy as therapeutic. This was in spite of a some-
what suggestive phrase in the consent form describing 
potential benefits due to “careful follow-up.” Instead, 
they consistently recalled altruism as their primary if 
not exclusive motivation to enroll in the parent study, 
understood they had participated in research, and per-
ceived the research biopsies correctly as nontherapeutic. 
They further recalled comprehending risk and ex-
pressed no surprise at the level of burden experienced. 
None of the respondents perceived pressure to enroll in 
the parent study, and several cited the consent process 
as evidence of voluntary decision-making. These find-
Interview responses from our study paint a  
reassuring picture about informed consent for  
research biopsies—respondents recruited from a 
parent study did not demonstrate a propensity to 
view an invasive nondiagnostic biopsy as  
therapeutic.
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ings are inconsistent with some studies suggesting that 
research participants occasionally view research biop-
sies as therapeutic.15 These differences may reflect our 
particular research site. They may also reflect the fact 
that respondents in our study were not participating in 
drug trials involving experimental treatments. Given 
the fluidity with which respondents transitioned from 
discussing treatment to research, differences may also 
reflect our sustained and careful probing of therapeutic 
perceptions.
Notwithstanding altruistic motivation for enrolling 
in the parent study, the answers respondents gave to 
our questions suggest they were preoccupied with their 
diagnosis and treatment during the consent process for 
the parent study. Most recalled being disengaged in the 
research itself, as indicated by rapid decision-making, 
scarce questioning, poor recollection of objectives, 
and little contemplation of research benefits. Instead, 
decision-making about the parent study was embedded 
within a network of trust relations toward the investi-
gators, institutions, and the research enterprise.16 That 
is, respondents generally entrusted moral and scientific 
matters relating to how the study was carried out to 
the research team and research systems. Disclosure 
elements during the consent process did not appear 
to play a direct role in decision-making, though the 
enactment of consent seemed to engender perceptions 
of researcher and institutional trustworthiness. These 
findings underline the point that informed consent is no 
substitute for independent risk and benefit review. They 
also make clear that informed consent and IRB review 
of protocols—in addition to serving substantive ethical 
ends—help sustain relationships that make burdensome 
research possible.17
Findings from our pilot study also leave many 
unanswered questions. To what extent are responses at 
this research site representative of other sites? Would 
perceptions about therapeutic orientation differ if the 
parent study had been an investigational drug trial? 
Where does the trust that underlies altruistic motiva-
tions originate, how is it sustained, and how resilient 
is it? And above all, are perceptions reported here a 
reliable proxy for perceptions of research participants 
during the informed consent process itself?
Our findings are subject to several limitations. First, 
our sample was small and limited to one site. Though 
interviews converged on key themes, our findings 
should be replicated before drawing conclusions about 
consent validity for studies that include a research 
biopsy. Second, interviews were conducted months, and 
in some cases years, after the biopsies were conducted, 
as we were unable to obtain permission from study in-
vestigators to interview patients during or immediately 
after the consent process for the parent studies. Recall 
of a consent process and of the information conveyed 
is an imperfect representation of the actual process and 
decision-making at that time, and respondents likely 
came to understand the research they were in and their 
relationship with the study team better after having 
participated in it. Third, the biopsy study team’s knowl-
edge that we were studying their consent process may 
have induced more scrupulous conduct. We consider 
this unlikely, however, as biopsies had been collected 
from most of our respondents before we initiated our 
research. Fourth, our research was partially funded 
by the team that conducted the biopsies. Maintaining 
critical distance from funders and parent-study investi-
gators is always a methodological challenge; we leave it 
to others to decide whether we effectively navigated this 
relationship.
Disclosure
The authors declare no commercial interest in the 
subject matter. However, this study was funded by, and 
involved collaboration with, scientific teams pursuing 
research biopsies.
Acknowledgments 
This work was funded by Genome Quebec (“Molecu-
lar Profiling of Drug-Resistant Triple Negative Breast 
Cancer”) and the Cancer Stem Cell Consortium (“Ethi-
cal, Legal, and Social Issues of Cancer Initiating Cell and 
Translational Medicine Research”). We thank Scott Kim 
and Ray De Vries for helpful discussions; faults remain our 
own. The authors would like to dedicate this paper in the 
memory of Kathleen Glass—a great mentor, colleague, and 
friend.
n Roberto Abadie, PhD, is project director at Social Networks 
Research Group, John Jay College of Criminal Justice, City Univer-
sity of New York, New York, NY; Jonathan Kimmelman, PhD, the 
corresponding author for this article, is associate professor in the 
Biomedical Ethics Unit, Department of Social Studies of Medicine, 
McGill University, Montreal, QC; Josiane Lafleur,  MSc, is clinical 
research associate in the Department of Oncology, Lady Davis Insti-
tute, Segal Cancer Center, Jewish General Hospital, Montreal, QC; 
Trudo Lemmens,  LicJur, LLM, DCL, is William M. Scholl Chair in 
Health Law and Policy, on the faculty of law, University of Toronto, 
Toronto, ON.
References
1. Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, 
Chabner BA. Trends in the use and role of biomarkers in phase I 
oncology trials. Clinical Cancer Research. 2007;13(22, pt. 1):6719-
6726.
 IRB: EthIcs & human REsEaRch may-JunE 2014
15
2. Overman MJ, Modak J, Kopetz S, et al. Use of research 
biopsies in clinical trials: Are risks and benefits adequately discussed? 
Journal of Clinical Oncology 2012;31(1):17-22; Hemmer JM, Kelder 
JC, van Heesewijk HP. Stereotactic large-core needle breast biopsy: 
Analysis of pain and discomfort related to the biopsy procedure. 
European Journal of Radiology 2008;18(2):351-354; Simon JR, 
Kalbhen CL, Cooper RA, Flisak ME. Accuracy and complication 
rates of US-guided vacuum-assisted core breast biopsy: Initial results. 
Radiology 2000;215(3):694-697; Szynglarewicz B, Matkowski R, 
Kasprzak P, et al. Pain experienced by patients during minimal-inva-
sive ultrasound-guided breast biopsy: Vacuum-assisted vs core-needle 
procedure. European Journal of Surgical Oncology 2011;37(5):398-
403; Watmough S, Flynn M. A review of pain management interven-
tions in bone marrow biopsy. Journal of Clinical Nursing 2011;20(5-
6):615-623; Brunetti GA, Tendas A, Meloni E, et al. Pain and anxiety 
associated with bone marrow aspiration and biopsy: A prospective 
study on 152 Italian patients with hematological malignancies. An-
nals of Hematology 2011;90(10):1233-1235; Liden Y, Olofsson N, 
Landgren O, Johansson E. Pain and anxiety during bone marrow 
aspiration/biopsy: Comparison of ratings among patients versus 
health-care professionals. European Journal of Oncology Nursing 
2012;16(3):323-329; Vanhelleputte P, Nijs K, Delforge M, et al. Pain 
during bone marrow aspiration: Prevalence and prevention. Journal 
of Pain and Symptom Management 2003;26(3):860-866.
3. Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic 
study of erlotinib in patients with advanced non-small cell lung 
cancer previously treated with platinum-based chemotherapy. Clinical 
Cancer Research 2008;14(12):3867-3874.
4. Helft P, Daugherty C. Are we taking without giving in return? 
The ethics of research-related biopsies and the benefits of clinical trial 
participation. Journal Clinical Oncology 2006;24:4793-4795.
5. Faden RR, Beauchamp TL, King NMP. A History and Theory 
of Informed Consent. New York: Oxford University Press, 1986, p. 
xv, p. 392.
6. Agulnik M, Oza A, Pond G, et al. Impact and perceptions of 
mandatory tumor biopsies for correlative studies in clinical trials of 
novel anticancer agents. Journal Clinical Oncology 2006;24:4801-
4807; Pentz RD, Harvey RD, White M, et al. Research biopsies in 
phase I studies: Views and perspectives of participants and investiga-
tors. IRB: Ethics & Human Research 2012;34(2):1-8.
7. Gutierrez ME, Kummar S, Horneffer Y, et al. Recruitment 
experience in a phase 0 trial of ABT-888, an inhibitor of poly (ADP-
ribose) polymerase (PARP), in patients (pts) with advanced malig-
nancies. Journal of Clinical Oncology (meeting abstracts). 2007;25 
supplement (18):14111; For a review see, Kimmelman J, Lemmens T, 
Kim SY. Analysis of consent validity for invasive, nondiagnostic re-
search procedures. IRB: Ethics & Human Research 2012;34(5):1-7.
8. Peppercorn J, Shapira I, Collyar D, et al. Ethics of mandatory 
research biopsy for correlative end points within clinical trials in 
oncology. Journal Clinical Oncology 2010;28(15):2635-2640.
9. Appelbaum PS, Roth LH, Lidz CW, et al. False hopes and best 
data: Consent to research and the therapeutic misconception. Hast-
ings Center Report 1987;17(2):20-24; Glannon W. Phase I oncology 
trials: Why the therapeutic misconception will not go away. Journal 
of Medical Ethics 2006;32(5):252-255.
10. See ref. 7, Kimmelman et al., 2012. 
11. Glaser B. Basics of Grounded Theory Analysis: Emergence vs. 
Forcing. Mill Valley, CA: Sociology Press, 1992.
12. Miles MB, Huberman AM. Qualitative Data Analysis: An 
Expanded Sourcebook, 2nd ed. Thousand Oaks, CA: Sage, 1994.
13. Van den Bergh KA, Essink-Bot ML, van Klaveren RJ, et al. 
Informed participation in a randomised controlled trial of computed 
tomography screening for lung cancer. European Respiratory Journal 
2009;34(3):711-720.
14. See ref. 5, Faden and Beauchamp 1986.
15. See ref. 6, Agulnik et al. 2006, Pentz et al. 2012.
16. Giddens A. The Consequences of Modernity. Stanford, CA: 
Stanford University Press, 1990, p. ix, p. 186.
17. London AJ, Kimmelman J, Emborg ME. Research ethics. 
Beyond access vs. protection in trials of innovative therapies. Science 
2010;328(5980):829-830.
